Abstract
Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKCmediated regulatory pathways, leading ultimately to a greater understanding of different cancers.
Current Pharmaceutical Design
Title: Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy
Volume: 7 Issue: 17
Author(s): Orla P. Barry and Marcelo G. Kazanietz
Affiliation:
Abstract: Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKCmediated regulatory pathways, leading ultimately to a greater understanding of different cancers.
Export Options
About this article
Cite this article as:
Orla P. Barry and Marcelo G. Kazanietz , Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy, Current Pharmaceutical Design 2001; 7 (17) . https://dx.doi.org/10.2174/1381612013397041
DOI https://dx.doi.org/10.2174/1381612013397041 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry Speciation of Metal Complexes of Medicinal Interest: Relationship between Solution Equilibria and Pharmaceutical Properties
Current Medicinal Chemistry Role of Farletuzumab in Epithelial Ovarian Carcinoma
Current Pharmaceutical Design Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Application of Nanobioinformatics in Medical Science – A Probable Therapy
Current Bioinformatics Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum
Current Topics in Medicinal Chemistry The Capability to Forecast Response to Therapy with Regard to The Time and Intensity of The Inflammatory Process in vitro in Dermal Fibroblasts Induced by IL-12
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Imaging in the Age of Molecular Medicine (Guest Editor: Fabian Kiessling)]
Current Pharmaceutical Biotechnology Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Use of Carbohydrate-Conjugated Nanoparticles for an Integrated Approach to Functional Imaging of Glycans and Understanding of their Molecular Mechanisms
Current Pharmaceutical Biotechnology Inorganic Nanoparticles for In Vitro Cancer Diagnosis: A Patent Review
Recent Patents on Nanomedicine Activation of B Cells by a Dendritic Cell-Targeted Oral Vaccine
Current Pharmaceutical Biotechnology Beclin 1 Biology and its Role in Heart Disease
Current Cardiology Reviews Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors
Current Pharmaceutical Design Comprehensive Profiling of the Low Molecular Weight Proteins and Peptides in Weak Cation Exchange Beads Human Serum Retentate
Protein & Peptide Letters The Activation of β<sub>1</sub>-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer
Current Cancer Drug Targets Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Current Pharmaceutical Design Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
Current Drug Targets